News
IONS
58.09
-0.07%
-0.04
Novartis Late-Stage Cardiovascular Outcome Study Fails, Stock Down
NASDAQ · 16h ago
Amgen Shares Fall as Novartis' Pelacarsen Misses Phase III Study Goal
NASDAQ · 16h ago
Citi sees limited immediate downside for Ionis after pelacarsen failure
TipRanks · 16h ago
Ionis Buy Rating Reiterated as Analyst Sees Limited Impact from Lp(a)HORIZON Setback and Maintains $100 Price Target
TipRanks · 17h ago
Weekly Report: what happened at IONS last week (0831-0904)?
Weekly Report · 22h ago
Does Pelacarsen’s Phase 3 Miss And ZANVASTRO’s FDA Win Change The Bull Case For Ionis (IONS)?
Simply Wall St · 2d ago
Stocks to Watch: Ionis Pharmaceuticals, Novartis, Corvex
Dow Jones · 3d ago
Ionis Pharmaceuticals Updates on Novartis Pelacarsen Trial Outcome
TipRanks · 3d ago
Ionis Pharmaceuticals falls after Pelacarsen fails key Phase 3 heart trial
Seeking Alpha · 3d ago
Novartis announces Phase 3 pelacarsen study did not meet primary endpoint
TipRanks · 3d ago
Novartis Says Pelacarsen Heart Disease Drug Missed Primary Endpoint -- Update
Dow Jones · 3d ago
Ionis Pharmaceuticals: Buy Rating Backed by FDA Approval of Zanvastro and Strengthened Neurology Pipeline Upside
TipRanks · 3d ago
Ionis: Downgrading To Sell After A Series Of Unfortunate Events
Seeking Alpha · 3d ago
Ionis Pharmaceuticals (IONS) Receives a Rating Update from a Top Analyst
TipRanks · 3d ago
This Biotech Wins a Big FDA Approval. Why Wall Street Is Shrugging.
Barron‘s · 3d ago
Ionis Pharmaceuticals Price Target Maintained With a $86.00/Share by Needham
Dow Jones · 3d ago
Needham Reiterates Buy on Ionis Pharmaceuticals, Maintains $86 Price Target
Benzinga · 3d ago
Analysts’ Opinions Are Mixed on These Healthcare Stocks: cbdMD (YCBD) and Ionis Pharmaceuticals (IONS)
TipRanks · 3d ago
Ionis Pharmaceuticals Is Maintained at Market Perform by BMO Capital
Dow Jones · 3d ago
Ionis Pharmaceuticals Price Target Raised to $61.00/Share From $60.00 by BMO Capital
Dow Jones · 3d ago
More
Webull provides a variety of real-time IONS stock news. You can receive the latest news about Ionis Pharmaceuticals through multiple platforms. This information may help you make smarter investment decisions.
About IONS
Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.